TipRanks
Advertisement
Advertisement
Adicet Bio Advances Prula-cel Toward Pivotal Lupus Trial
PremiumCompany AnnouncementsAdicet Bio Advances Prula-cel Toward Pivotal Lupus Trial
22d ago
Adicet Bio reports data from Phase 1 study of prula-cel
Premium
The Fly
Adicet Bio reports data from Phase 1 study of prula-cel
22d ago
Adicet data update presents attractive opportunity, says H.C. Wainwright
Premium
The Fly
Adicet data update presents attractive opportunity, says H.C. Wainwright
1M ago
Adicet Bio: Buy Rating Reiterated on Strong 2Q26 Results, Extended Cash Runway, and Multiple Upcoming Clinical Catalysts Supporting $27 DCF-Based Price Target
PremiumRatingsAdicet Bio: Buy Rating Reiterated on Strong 2Q26 Results, Extended Cash Runway, and Multiple Upcoming Clinical Catalysts Supporting $27 DCF-Based Price Target
2M ago
Adicet Bio price target lowered to $90 from $100 at Guggenheim
Premium
The Fly
Adicet Bio price target lowered to $90 from $100 at Guggenheim
2M ago
Adicet Bio reports Q2 EPS ($1.99), consensus ($1.64)
Premium
The Fly
Adicet Bio reports Q2 EPS ($1.99), consensus ($1.64)
3M ago
Range, Adicet, Nova, PBF, Dorian: Insider Shake-Up
PremiumWeekend UpdatesRange, Adicet, Nova, PBF, Dorian: Insider Shake-Up
6M ago
Adicet Bio: Cash Runway to 2027 and Differentiated Allogeneic Prula‑cel Pipeline Support Buy Rating and $27 Target
Premium
Ratings
Adicet Bio: Cash Runway to 2027 and Differentiated Allogeneic Prula‑cel Pipeline Support Buy Rating and $27 Target
7M ago
Adicet Bio price target lowered to $27 from $50 at H.C. Wainwright
Premium
The Fly
Adicet Bio price target lowered to $27 from $50 at H.C. Wainwright
7M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―